Clinical Trials for Ischemic Heart Disease
197 ischemic heart disease trials indexed, 85 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Ischemic Heart Disease
Ischemic Heart Disease (IHD), also known as coronary artery disease, occurs when the blood supply to the heart muscle is reduced or blocked. This happens because of the buildup of plaque inside the coronary arteries, a process called atherosclerosis. The heart muscle needs a constant supply of oxygen-rich blood to function properly, and when the arteries narrow, the heart receives less oxygen. Doctors diagnose IHD using tests such as electrocardiograms (ECG), stress tests, coronary angiography, and blood tests that measure heart enzymes. These tools help identify the extent of artery blockage and any damage to the heart muscle.
Common symptoms of Ischemic Heart Disease include chest pain or discomfort (angina), shortness of breath, fatigue, and sometimes heart palpitations. Symptoms often appear during physical activity or emotional stress when the heart requires more oxygen. The typical age of onset is around 50 years or older, but it can develop earlier, especially in people with strong risk factors. Men tend to be affected more often than women, though the risk for women increases after menopause. Major risk factors include high blood pressure, high cholesterol, smoking, diabetes, obesity, and a family history of heart disease.
Ischemic Heart Disease is a leading cause of death worldwide and has a significant impact on public health. According to the World Health Organization, it accounts for about 16% of all deaths globally. In the United States alone, millions live with IHD, and it is responsible for nearly one in seven deaths. The economic burden is also high, with costs related to hospital care, medications, and lost productivity. Early diagnosis and management are crucial because untreated IHD can lead to heart attacks, heart failure, or sudden cardiac death.
The Ischemic Heart Disease Treatment Landscape
The first-line treatment for Ischemic Heart Disease usually focuses on lifestyle changes and medications to reduce symptoms and prevent complications. Patients are often advised to adopt a heart-healthy diet, increase physical activity, quit smoking, and manage stress. Medications such as aspirin help prevent blood clots, while beta-blockers lower heart rate and blood pressure. Statins are used to reduce cholesterol levels and slow the progression of plaque buildup. In some cases, procedures like angioplasty or coronary artery bypass surgery may be needed to restore blood flow.
When first-line treatments are not enough, second- and third-line options come into play. These may include drugs such as calcium channel blockers, nitrates, and newer antiplatelet agents that further improve blood flow and reduce symptoms. For patients who do not respond well to standard therapies, additional options like ranolazine or ivabradine may be considered. Invasive procedures may be repeated or expanded depending on disease severity. It is important to tailor treatment to each patient’s needs, considering factors like other health conditions and medication tolerance.
Despite advances in treatment, some patients still face challenges. Certain subgroups, such as those with diabetes or chronic kidney disease, may respond poorly to existing therapies. Side effects from medications can limit their use, and some patients develop resistance to drugs like aspirin. Researchers are working to address these gaps by exploring new drug classes, improving stent technology, and testing combination therapies. Clinical trials are essential for identifying better ways to manage symptoms and improve long-term outcomes for all patients.
Why Clinical Trials Matter for Ischemic Heart Disease
Clinical trials offer patients with Ischemic Heart Disease access to new treatments that are not yet widely available. Participating in a trial may provide closer medical monitoring and the opportunity to contribute to scientific knowledge that could help others in the future. According to ClinicalTrials.gov, there are currently 197 clinical trials related to Ischemic Heart Disease, with 85 actively recruiting participants. These studies cover a range of approaches, from new medications to devices and lifestyle interventions, aiming to improve care and reduce complications.
Taking part in a clinical trial also involves some risks. The effectiveness of new treatments is not guaranteed, and some participants may receive a placebo instead of the active drug. Additional clinic visits and tests may be required, which can be time-consuming. Side effects from experimental treatments are possible and may be unknown at the start of the study. It is important for patients to discuss these risks and benefits carefully with their healthcare providers before enrolling.
The landscape of clinical trial sponsors includes academic institutions, pharmaceutical companies, and cooperative research groups. Each plays a role in advancing knowledge about Ischemic Heart Disease. ClinicalTrials.gov serves as a central registry where patients and caregivers can find up-to-date information about ongoing studies. This transparency helps people make informed decisions about participation and supports the development of new treatment options that may improve quality of life and survival rates.
What to Look for in a Ischemic Heart Disease Clinical Trial
Clinical trials are typically divided into four phases. Phase 1 trials test a new treatment in a small group to evaluate safety and dosage. Phase 2 trials involve more participants to assess effectiveness and side effects. Phase 3 trials compare the new treatment to the current standard in larger groups. Phase 4 trials occur after approval to monitor long-term effects and safety. For ischemic heart disease, many trials do not specify a phase, with 89 listed as NA. Phase 4 trials are the most common among those with a known phase, totaling 13. Phase 2 and Phase 3 trials follow, with 11 and 6 respectively.
Inclusion criteria for ischemic heart disease trials vary but often focus on age, previous treatments, and disease specifics. Most trials include adults typically between 18 and 75 years old. Participants may need to have had prior treatments such as angioplasty or medication for heart disease. Biomarkers like cholesterol levels or specific heart enzymes might be required to qualify. Some trials look for certain stages of ischemic heart disease, such as stable angina or recent heart attack. The length of time a patient has had the disease can also be a factor in eligibility.
Exclusion criteria help protect participants and ensure clear results. Patients with other serious health conditions, like uncontrolled diabetes or kidney failure, are often excluded. This is because these comorbidities could affect the safety of the treatment or the study’s outcomes. Drug interactions are another common reason for exclusion. Participants taking medications that could interfere with the trial drug may not qualify. Safety thresholds, such as limits on blood pressure or heart function, are set to reduce risks during the study.
Practical considerations matter when deciding to join a trial. The length of the trial can range from a few months to several years. Visit schedules vary as well, with some requiring frequent clinic visits and others less often. Travel distance to the study site is important to consider, especially for older adults or those with mobility issues. When speaking with the research team, patients should ask: How long will the trial last? What are the possible side effects? How often will I need to visit the clinic? What happens if I decide to leave the trial early?
Primary Sources and Further Reading
For more detailed information about ischemic heart disease and clinical trials, it helps to consult trusted health resources. These sources offer reliable, up-to-date facts on heart disease, treatment options, and ongoing research. They can also guide patients and caregivers in understanding clinical trial processes and safety measures.
- MedlinePlus: Ischemic Heart Disease
- National Heart, Lung, and Blood Institute: Ischemic Heart Disease
- ClinicalTrials.gov: Ischemic Heart Disease Studies
- Centers for Disease Control and Prevention: Ischemic Heart Disease
Latest Research and Emerging Treatments for Ischemic Heart Disease (2026)
Ongoing ischemic heart disease research is exploring several new drugs and therapies that could improve patient outcomes. One Phase 3 trial is studying the anti-inflammatory drug ziltivekimab in patients who recently had a heart attack. This drug targets inflammation, which plays a role in artery plaque buildup. Early data suggests that reducing inflammation may slow disease progression and lower the risk of future heart problems. For patients, this could mean fewer complications after a heart attack and better long-term artery health.
Another study is testing inclisiran, a drug added to statin therapy, in adults with non-obstructive coronary artery disease. Inclisiran works by lowering LDL cholesterol, which contributes to plaque formation in arteries. Trials are assessing whether inclisiran can further reduce plaque buildup when combined with standard statins. If successful, this ischemic heart disease new treatment 2026 could offer an additional way to control cholesterol and protect heart vessels.
There is also a trial investigating a combination pill of obicetrapib and ezetimibe for people with high-risk atherosclerotic cardiovascular disease. Obicetrapib may help raise good cholesterol (HDL) levels, while ezetimibe lowers cholesterol absorption in the intestines. Together, they aim to reduce coronary plaque more effectively than current treatments. For patients, this could mean better management of cholesterol and a lower chance of heart attacks or other ischemic heart disease complications. Additionally, a study on intravenous acetaminophen is exploring whether it can prevent delirium after cardiac surgery, which is a common issue for older adults recovering from heart procedures. This research highlights the broad scope of ischemic heart disease treatment efforts in 2026, focusing not only on heart health but also on improving recovery and quality of life after surgery.
Frequently asked questions about Ischemic Heart Disease trials
How do I find Ischemic Heart Disease clinical trials?
The authoritative source for Ischemic Heart Disease clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 197 ischemic heart disease studies are currently indexed. You can search by entering "ischemic heart disease" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new ischemic heart disease trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Ischemic Heart Disease trials in?
Across the 197 ischemic heart disease trials TrialsAlert indexes, the most common phase is Phase 4. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Ischemic Heart Disease clinical trials are currently recruiting?
As of the latest scan, 85 ischemic heart disease trials have a "Recruiting" status on ClinicalTrials.gov, out of 197 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting ischemic heart disease trial matches their tracked condition.
Stay informed about ischemic heart disease research
Get a weekly briefing with the trials that matter most.